AN2 Therapeutics

Q2 FY2026 EarningsQ2 FY2026 results outperformed consensus on the bottom line: net loss of $8.2M was narrower than the expected $10.5M, while Diluted EPS of -$0.18 beat the consensus of -$0.23. The revenue of $0 was in-line with expectations for this clinical-stage biotech. Stronger-than-expected performance was driven by a 28% YoY reduction in G&A expenses, despite R&D scaling up by 88% YoY to support three Phase 2 programs. The company projects a significant cash runway extending into 2029.